Dyadic International to Present at The MicroCap Conference on October 2nd in New York City at the Essex House

NEW YORK, NY / ACCESSWIRE / September 17, 2018 / Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, today announced that Ping W. Rawson, Chief Accounting Officer, will be presenting at this year’s MicroCap Conference on Tuesday, October 2nd at 2:30 p.m. ET in New York City. Ms. Rawson will also be available to meet with investors at the conference.

A live webcast of the presentation may be accessed on the conference’s website at http://wsw.com/webcast/microcapconf8/dyai/. The webcast and presentation will be archived for 90 days following the event on the company’s website at www.dyadic.com.

CONFERENCE OVERVIEW AND STRUCTURE

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.

The MicroCap Conference will take place in New York City at the Essex House on October 1st and 2nd. Registration will begin on Monday at 7:00AM and will last until the evening. These days will be jam-packed with company presentations, 1-on-1 meetings, roundtables, expert panel discussions, and plenty of time to network with other investors over food and drinks.

REGISTRATION FOR INVESTORS

To request free registration, please go to our website (www.microcapconf.com), and click the “Registration” button.

PARTICIPATING COMPANIES

For our most updated list of companies, please go to our website (www.microcapconf.com).

MARQUEE SPONSOR

Maxim Group

The Special Equities Group

PLATINUM SPONSOR

Interactive Offers

M2 Compliance

OTHER SPONSORS

MZ Group

Irth Communications

Gillon Tax Advisors

Harter Secrest & Emery LLP

Regal Consulting

Proactive Investors

Hunter Taubman Fischer & LI LLC

Equities.com

Issuer Direct

The Money Channel

C6 Capital

Marcum

Equisolve

PCG Advisory Group

CoreIR

Berg Capital Markets, LLC

News Compliments of ACCESSWIRE.

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Ashley Allard at ashley@microcapconf.com

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic’s website at http://www.dyadic.com for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.

Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic in the Company’s annual and quarterly reports which are filed with the OTC markets. Please visit the OTC markets website at www.otcmarkets.com/stock/DYAI/quote.

Investor Contact:

Dyadic International, Inc.
Ping W. Rawson
Chief Accounting Officer
Phone: (561) 743-8333
Email: dyadic@info.dyadic.com

SOURCE: Dyadic International, Inc.

ReleaseID: 512081